Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Peak Cough Flow and Cough Clearance in Patients With Muscular Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02034305
Recruitment Status : Completed
First Posted : January 13, 2014
Last Update Posted : January 6, 2021
Sponsor:
Collaborator:
Respirtech, Inc.
Information provided by (Responsible Party):
Daniel J. Weiner, University of Pittsburgh

Brief Summary:
This study is to determine whether physiologic measures (peak cough flow, measures of respiratory muscle strength including MIP, MEP ,SNIP, and spirometry) can predict spontaneous cough clearance (as measured by a nuclear medicine study) in children with neuromuscular disease. It will also determine whether airway clearance is augmented by high frequency chest wall oscillation.

Condition or disease
Duchenne Muscular Dystrophy

Layout table for study information
Study Type : Observational
Actual Enrollment : 7 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Pilot Study of Cough Peak Flow And Airway Clearance in Pediatric Patients With Neuromuscular Disease
Study Start Date : January 2014
Actual Primary Completion Date : January 1, 2021
Actual Study Completion Date : January 1, 2021





Primary Outcome Measures :
  1. Spontaneous cough clearance [ Time Frame: Assessed at multiple time points over 30 minutes ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Boys 6-21 years of age with Duchenne Muscular Dystrophy
Criteria

Inclusion Criteria:

  • Age 6-21; able to cooperate with study procedures
  • Duchenne Muscular Dystrophy OR Becker Muscular Dystrophy

Exclusion Criteria:

  • Need for mechanical ventilation during the day
  • Recent (within 2 weeks) lower respiratory tract infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02034305


Locations
Layout table for location information
United States, Pennsylvania
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15224
Sponsors and Collaborators
University of Pittsburgh
Respirtech, Inc.
Layout table for additonal information
Responsible Party: Daniel J. Weiner, Associate Professor of Pediatrics, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT02034305    
Other Study ID Numbers: PRO11100704
First Posted: January 13, 2014    Key Record Dates
Last Update Posted: January 6, 2021
Last Verified: January 2021
Keywords provided by Daniel J. Weiner, University of Pittsburgh:
Airway Clearance
Duchenne Muscular Dystrophy
Peak Cough Flow
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Cough
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Genetic Diseases, X-Linked